Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Cyteir Therapeutics, Inc.
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)